These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 17212186)
41. Molecular epidemiology of paediatric invasive pneumococcal disease in southern Spain after the introduction of heptavalent pneumococcal conjugate vaccine. Obando I; Arroyo LA; Sánchez-Tatay D; Tarragó D; Moreno D; Hausdorff WP; Brueggemann AB Clin Microbiol Infect; 2007 Mar; 13(3):347-8. PubMed ID: 17391398 [No Abstract] [Full Text] [Related]
42. Antibiotic resistance in Latin America: a cause for alarm. Valenzuela MT; de Quadros C Vaccine; 2009 Aug; 27 Suppl 3():C25-8. PubMed ID: 19540634 [TBL] [Abstract][Full Text] [Related]
43. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451 [TBL] [Abstract][Full Text] [Related]
44. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612 [TBL] [Abstract][Full Text] [Related]
45. Use of pneumococcal vaccine. Yeager AS West J Med; 1980 Jan; 132(1):63-4. PubMed ID: 7376650 [No Abstract] [Full Text] [Related]
46. Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children. Park SY; Moore MR; Bruden DL; Hyde TB; Reasonover AL; Harker-Jones M; Rudolph KM; Hurlburt DA; Parks DJ; Parkinson AJ; Schuchat A; Hennessy TW Pediatr Infect Dis J; 2008 Apr; 27(4):335-40. PubMed ID: 18316986 [TBL] [Abstract][Full Text] [Related]
47. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449 [TBL] [Abstract][Full Text] [Related]
48. Clinical characteristics of a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine candidate (PHiD-CV). Introduction. Dagan R; Frasch C Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S63-5. PubMed ID: 19325448 [No Abstract] [Full Text] [Related]
49. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Nelson JC; Jackson M; Yu O; Whitney CG; Bounds L; Bittner R; Zavitkovsky A; Jackson LA Vaccine; 2008 Sep; 26(38):4947-54. PubMed ID: 18662735 [TBL] [Abstract][Full Text] [Related]
50. Five-fold increase in pediatric parapneumonic empyema since introduction of pneumococcal conjugate vaccine. Hendrickson DJ; Blumberg DA; Joad JP; Jhawar S; McDonald RJ Pediatr Infect Dis J; 2008 Nov; 27(11):1030-2. PubMed ID: 18845981 [TBL] [Abstract][Full Text] [Related]
51. Raising the profile of pneumococcal disease. Murdoch DR Intern Med J; 2008 Jun; 38(6):381-3. PubMed ID: 18613895 [No Abstract] [Full Text] [Related]
52. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pavia M; Bianco A; Nobile CG; Marinelli P; Angelillo IF Pediatrics; 2009 Jun; 123(6):e1103-10. PubMed ID: 19482744 [TBL] [Abstract][Full Text] [Related]
53. The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae. McGee L Curr Opin Microbiol; 2007 Oct; 10(5):473-8. PubMed ID: 17936680 [TBL] [Abstract][Full Text] [Related]
54. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247 [TBL] [Abstract][Full Text] [Related]
55. Serotype replacement in perspective. Dagan R Vaccine; 2009 Aug; 27 Suppl 3():C22-4. PubMed ID: 19545935 [TBL] [Abstract][Full Text] [Related]
56. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Hsieh YC; Lin PY; Chiu CH; Huang YC; Chang KY; Liao CH; Chiu NC; Chuang YC; Chen PY; Chang SC; Liu JW; Yen MY; Wang JH; Liu CY; Lin TY Vaccine; 2009 Sep; 27(40):5513-8. PubMed ID: 19615960 [TBL] [Abstract][Full Text] [Related]
57. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006. Motlova J; Benes C; Kriz P Epidemiol Infect; 2009 Apr; 137(4):562-9. PubMed ID: 18796171 [TBL] [Abstract][Full Text] [Related]
58. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Messina AF; Katz-Gaynor K; Barton T; Ahmad N; Ghaffar F; Rasko D; McCracken GH Pediatr Infect Dis J; 2007 Jun; 26(6):461-7. PubMed ID: 17529859 [TBL] [Abstract][Full Text] [Related]
60. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]